Tretiva 25 Capsule (Isotretinoin 25mg)

Description

Tretiva 25 Capsule (Isotretinoin 25mg) — Complete Clinical and Patient Information Guide

Product Overview

Tretiva 25 Capsule (Isotretinoin 25mg) contains Isotretinoin 25mg as its active pharmaceutical ingredient. It belongs to the oral retinoid (vitamin A derivative) — most effective anti-acne agent available and is clinically indicated for severe nodulo-cystic acne vulgaris, moderate acne unresponsive to conventional treatment (topical retinoids, benzoyl peroxide, antibiotics), acne scarring risk, and acne significantly impacting psychological wellbeing. This information guide has been developed in accordance with YMYL (Your Money Your Life) standards, drawing on established pharmacological literature, regulatory prescribing information, and peer-reviewed clinical evidence to provide accurate, balanced, and medically responsible product information for patients and healthcare professionals.

Tretiva 25mg contains Isotretinoin 25mg, providing access to the most effective pharmacological treatment for severe acne available. Isotretinoin is the only acne medication that addresses all four pathological drivers of acne vulgaris simultaneously — excess sebum production, follicular hyperkeratinisation, C. acnes colonisation, and dermal inflammation — producing complete or near-complete acne clearance in the majority of patients after a single therapeutic course. Tretiva 25mg from Intas Pharma provides an intermediate dose between the standard 20mg and 30mg strengths, enabling precise dose titration.

About Tretiva 25mg and Its Active Ingredient

Isotretinoin 25mg is the active pharmaceutical ingredient in Tretiva 25mg. The drug belongs to the oral retinoid (vitamin A derivative) — most effective anti-acne agent available, a pharmacological class with a well-established clinical evidence base spanning multiple decades of research and real-world clinical use. Understanding the pharmacology, appropriate use, and safety considerations of this medication is essential for achieving optimal therapeutic outcomes while minimising risks — the hallmarks of evidence-based prescribing and responsible patient self-care.

Before initiating therapy with Tretiva 25mg, patients should disclose their complete medical history, all prescription and over-the-counter medications, herbal supplements, and known allergies to their prescribing physician or pharmacist. Medical supervision is particularly important for conditions classified as YMYL — where the consequences of improper use, incorrect diagnosis, or drug interactions could significantly impact health outcomes.

Mechanism of Action

Isotretinoin (13-cis-retinoic acid) is a vitamin A derivative (retinoid) that exerts its anti-acne effects through multiple complementary mechanisms that collectively target all four pathological drivers of acne vulgaris. First, isotretinoin binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in sebaceous gland cells, modulating transcription of genes controlling sebocyte differentiation and proliferation. This dramatically reduces sebaceous gland size (by 35–58%) and sebum production (by 70–90%) — directly eliminating the substrate for Cutibacterium acnes (C. acnes) growth. Second, normalisation of follicular keratinisation prevents microcomedone formation — the initiating lesion of all acne. Third, the reduction in sebum creates an inhospitable environment for C. acnes, reducing bacterial colonisation without directly killing bacteria (avoiding resistance). Fourth, isotretinoin exerts direct anti-inflammatory activity by suppressing cytokine production, inhibiting matrix metalloproteinase activity, and modulating neutrophil function in the dermis. These four simultaneous mechanisms account for isotretinoin’s unparalleled efficacy — producing complete remission in 80–85% of patients after a single course.

A clear understanding of the mechanism of action helps explain why this medication must be used under specific conditions — why timing relative to meals or sexual activity matters, why certain drug combinations are dangerous, and why the full course of treatment is necessary for maximum benefit. Healthcare providers use mechanistic knowledge to individualise therapy and anticipate interactions.

Clinical Indications

Tretiva 25 Capsule (Isotretinoin 25mg) is indicated for:

• Primary indication: severe nodulo-cystic acne vulgaris, moderate acne unresponsive to conventional treatment (topical retinoids, benzoyl peroxide, antibiotics), acne scarring risk, and acne significantly impacting psychological wellbeing
• Confirmed diagnosis required: Self-diagnosis and self-treatment of conditions managed by prescription medications is strongly discouraged. A qualified physician or specialist should confirm the diagnosis and determine whether this medication is appropriate for the individual patient’s circumstances.
• Treatment goals: The prescribing physician will establish clear therapeutic endpoints — symptom relief, functional improvement, laboratory targets, or lesion clearance — and will monitor response and adjust therapy accordingly.

Dosage and Administration

Isotretinoin dose is calculated based on body weight: the target cumulative dose is 120–150mg/kg over the treatment course (typically 4–6 months). 25mg is one component of the individualised daily dose determined by your dermatologist. Take with the largest meal of the day (isotretinoin is fat-soluble — a fatty meal doubles systemic absorption). Do not split or open capsules. Do not alter the dose without dermatologist approval.

Adherence to the prescribed dosing schedule is critical for achieving therapeutic efficacy and minimising the risk of adverse effects. Patients who are uncertain about their dosing regimen should contact their prescribing physician or pharmacist before making any changes. Never adjust the dose or stop therapy without medical advice.

Who Should Use Tretiva 25mg

Tretiva 25mg is appropriate for adult patients who have been diagnosed by a qualified healthcare professional with the conditions listed above and for whom this specific formulation has been prescribed or recommended. Patients with the relevant confirmed diagnosis who have no contraindications to the active ingredient are appropriate candidates.

Contraindications — Who Should Not Use Tretiva 25mg

Pregnancy (Category X — absolute contraindication; teratogenic at any dose in first trimester). Women of childbearing potential must have a negative pregnancy test before starting, use two reliable contraception methods throughout treatment and for 1 month after stopping, and have monthly pregnancy testing. Breastfeeding. Hypersensitivity to isotretinoin, other retinoids, or parabens (used as preservative in some formulations). Severe hepatic impairment. Markedly elevated triglycerides (>800mg/dL). Hypervitaminosis A. Concurrent use with tetracycline antibiotics (increased pseudotumour cerebri risk — contraindicated combination). Concurrent use with vitamin A supplements. Wax epilation, dermabrasion, laser skin resurfacing are contraindicated during and for 6 months post-treatment due to increased skin fragility.

Patients should inform their healthcare provider of all medical conditions and medications before starting Tretiva 25mg. Self-medication without medical supervision — particularly for prescription medications — carries significant risks including delayed diagnosis of underlying conditions, inappropriate drug use, and preventable adverse effects or drug interactions.

Drug Interactions

Tetracycline antibiotics (minocycline, doxycycline, tetracycline) — concurrent use dramatically increases risk of pseudotumour cerebri (intracranial hypertension) — absolutely contraindicated combination. Vitamin A supplements — additive hypervitaminosis A toxicity. Methotrexate — additive hepatotoxicity risk. Alcohol — increases hepatotoxicity risk and may cause re-esterification to teratogenic etretinate. Progestin-only oral contraceptives — may be less effective; use two forms of contraception. Wax epilation and dermabrasion/laser procedures — avoid during treatment and for 6 months after due to increased skin fragility and scarring risk.

Before starting Tretiva 25mg, perform a complete medication review with a pharmacist or physician. Drug interactions can be clinically significant and potentially dangerous. Many interactions can be managed by dose adjustment, timing modification, or alternative drug selection — but only when identified and evaluated by a qualified professional.

Adverse Effects and Side Effects

Universal (virtually all patients): Mucocutaneous dryness — dry lips (cheilitis), dry skin, dry nasal mucosa, dry eyes (reduced contact lens tolerance), and dry mouth are expected in essentially all patients and reflect the drug’s sebum-suppressing action. These effects are dose-dependent and managed with intensive moisturisation and lip care.

Common (>10%): Elevated serum triglycerides and cholesterol (requires monitoring), elevated liver transaminases (ALT/AST), photosensitivity (reduced tolerance to UV exposure — strict SPF 50+ protection mandatory), musculoskeletal pain and myalgia, epistaxis from nasal mucosal dryness, and mild hair thinning (usually temporary).

Serious (requiring monitoring/management): Teratogenicity — isotretinoin is a Category X teratogen producing severe foetal malformations (craniofacial, cardiac, thymic, CNS) in virtually all exposed first-trimester pregnancies. Two reliable contraception methods are mandatory throughout therapy and for 1 month after cessation in all women of childbearing potential. Psychiatric effects — depression, mood changes, and (very rarely) suicidal ideation have been reported; the causal relationship remains debated but warrants monitoring and patient/family counselling. Pseudotumour cerebri (intracranial hypertension) — especially risk increases with concurrent tetracycline use (do not combine). Inflammatory bowel disease — rare cases reported. Skeletal effects with high cumulative doses — premature epiphyseal closure in growing adolescents (use lowest effective dose).

Not all patients experience side effects, and many effects are dose-dependent, transient, or manageable with appropriate supportive measures. Patients should be educated about which side effects require urgent medical attention (severe allergic reactions, priapism for ED medications, signs of intracranial hypertension with retinoids) versus those that are expected and manageable (initial dryness with isotretinoin, retinisation with tretinoin).

Special Population Considerations

Pregnancy: Topical retinoids, isotretinoin, and systemic retinoids are teratogenic and contraindicated in pregnancy. Topical clindamycin and benzoyl peroxide are generally considered safe in pregnancy under medical guidance. Hydroquinone should be avoided in pregnancy.

Paediatric use: Acne treatment in children under 12 should be supervised by a paediatric dermatologist. Minocycline and other tetracyclines are contraindicated under 8 years. Topical agents should be used with care on developing skin.

Darker skin phototypes (Fitzpatrick IV–VI): Patients with darker skin are at higher risk of post-inflammatory hyperpigmentation from inflammatory acne, making prompt treatment important. Irritant retinoids should be introduced slowly. Hydroquinone is effective for PIH but ochronosis risk with prolonged use is higher in darker phototypes — use minimum effective concentration with sun protection.

Sun protection: Essential for all patients using topical retinoids, hydroquinone, or oral minocycline. Daily SPF 30+ broad-spectrum sunscreen significantly improves outcomes and prevents relapse of hyperpigmentation.

Pregnancy prevention programme: All prescribers of isotretinoin must enrol female patients in a pregnancy prevention programme (iPLEDGE in USA; similar programmes in other countries). Monthly pregnancy tests, counselling on teratogenicity, and confirmed use of two methods of contraception are mandatory requirements for prescribing isotretinoin to women of childbearing potential. Isotretinoin must not be prescribed without formal documentation of pregnancy prevention compliance.

Storage and Handling

Store Tretiva 25mg at room temperature (15–25°C), away from direct sunlight, heat sources, and moisture. Keep in original manufacturer’s packaging until required. Store securely out of reach of children and pets. Do not use beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back services — do not flush or dispose in household waste.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in the original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for the next scheduled dose. Do not double-dose. For as-needed medications (PDE5 inhibitors, dapoxetine), the concept of a missed dose does not apply — take when required before sexual activity.

Q: Can I stop this medication abruptly?
A: For most topical acne treatments, stopping does not cause withdrawal, though acne may gradually return. For isotretinoin, complete the prescribed course for maximum benefit. For oral antibiotics, complete the full prescribed course. For PDE5 inhibitors, these are as-needed — no tapering required.

Q: How long does an isotretinoin course last?
A: Most courses last 4–6 months (16–24 weeks), targeting a cumulative dose of 120–150mg/kg of body weight. Longer courses at lower doses may also be prescribed. The cumulative dose, not the duration, determines the likelihood of sustained remission.

Q: Will my acne get worse before it gets better?
A: Many patients experience an initial flare of acne in the first 4–8 weeks of isotretinoin treatment as existing follicular plugs are expelled. This is expected and usually manageable. Maximum improvement typically occurs 4–6 weeks after completing the course as post-treatment skin remodelling continues.

Q: What blood tests do I need during isotretinoin therapy?
A: Before starting: pregnancy test (women), liver function tests (LFTs), fasting lipid panel, full blood count. During treatment: LFTs and lipids monthly or at intervals determined by your dermatologist. Serum pregnancy tests monthly for women. Alert your dermatologist immediately if you develop severe headache, visual disturbance, or jaundice during treatment.

Important Medical Disclaimer

This product information page is provided for general educational purposes and is intended to support — not replace — the professional judgement of qualified healthcare providers. All information has been prepared in accordance with YMYL (Your Money Your Life) standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. Drug therapy decisions must be individualised by a licensed physician or pharmacist with full knowledge of the patient’s medical history, comorbidities, and concurrent medications. Self-diagnosis and self-treatment carry significant health risks. If you have questions about this medication or your condition, consult your doctor, dermatologist, or pharmacist.